Deal price now drives SpringWorks
- Merck KGaA agreed to buy SpringWorks for $47.00 per share in cash, so the stock is now mainly a deal-closing story.
- OGSIVEO remains the main product today, with $44.1 million of U.S. net product revenue in Q1 2025.
- GOMEKLI became the second approved drug and posted $4.9 million of U.S. net product revenue in Q1 2025.
- The bull case is simple: the merger closes on time and holders receive the agreed cash price.
- The bear case is that the deal breaks, forcing investors to value SpringWorks as a standalone biotech again.
- Brimarafenib is no longer part of the upside case because SpringWorks and BeiGene are winding down MapKure.
A biotech stock turned deal bet
SpringWorks used to be a commercial launch story. That changed when Merck KGaA agreed to buy the company for $47.00 per share in cash. From here, the main question is not whether OGSIVEO or GOMEKLI can grow fast enough. It is whether the merger closes as planned.
The bull case is a merger arbitrage case. That means an investor is betting the deal closes and shareholders receive the cash price. The two approved drugs help explain why Merck KGaA wants the company. In Q1 2025, OGSIVEO produced $44.1 million of U.S. net product revenue, while newly launched GOMEKLI produced $4.9 million.
The bear case is also clear. If the merger fails because of a vote, a regulatory issue, or another closing problem, the stock would likely stop trading near the deal price. Investors would then have to value SpringWorks on its own drug sales, pipeline, cash needs, and launch risks. That value could be below $47.00 per share.
The next signals are practical ones: the shareholder vote, the Hart-Scott-Rodino waiting period, any other required regulatory approvals, and the final closing date. Until those are settled, operating updates matter, but they are secondary.
Two drugs, one buyer waiting
SpringWorks is a commercial-stage biotech. It develops targeted medicines for rare diseases and cancer, then sells approved drugs directly in the United States. Its two revenue products are OGSIVEO and GOMEKLI.
OGSIVEO treats adult patients with progressing desmoid tumors. GOMEKLI treats adults and children age 2 and older with NF1-associated plexiform neurofibromas. Both are oral drugs, which means patients take them by mouth instead of by infusion.
The company also has pipeline work. It is studying nirogacestat in ovarian granulosa cell tumors and in combinations with BCMA-directed multiple myeloma therapies. It is also testing SW-682, a TEAD inhibitor, in Phase 1a. The brimarafenib work through MapKure is being wound down after the partners reviewed trial data.
If the Merck KGaA deal closes, public shareholders exit for cash and the commercial execution risk moves to the buyer. If it does not close, SpringWorks must keep funding launches, trials, and possible Europe expansion on its own.
The drugs Merck KGaA wants
OGSIVEO
OGSIVEO is nirogacestat, an oral gamma secretase inhibitor. It was approved by the FDA in November 2023 for adult patients with progressing desmoid tumors and generated $44.1 million of U.S. net product revenue in Q1 2025.
GOMEKLI
GOMEKLI is mirdametinib, an oral MEK inhibitor. It was approved by the FDA on February 11, 2025 for adult and pediatric patients age 2 and older with NF1-associated plexiform neurofibromas, and generated $4.9 million of U.S. net product revenue in Q1 2025.
Nirogacestat in ovarian GCT
SpringWorks is testing nirogacestat in ovarian granulosa cell tumors, a rare tumor type. This is not the main stock driver while the merger is pending, but it could add value if the company were valued on a standalone basis.
Nirogacestat combinations in multiple myeloma
The company is also studying nirogacestat with BCMA-directed therapies for multiple myeloma. This is a pipeline option tied to combination treatment, not current product revenue.
SW-682
SW-682 is a TEAD inhibitor in a Phase 1a trial. Early-stage programs can be valuable, but they carry high clinical risk because safety and effect still need to be proven.
Brimarafenib and MapKure
SpringWorks and BeiGene decided to wind down MapKure and stop further investment in brimarafenib. This removes that program from the upside case.
Q1 revenue is still product-heavy
For the three months ended March 31, 2025, disclosed net product revenue came from two U.S. products: OGSIVEO and GOMEKLI. SpringWorks reports as one operating segment, so this mix is shown by product revenue rather than by formal business segment.
What can still go wrong
Merger fails to close
High impact · Medium oddsThe biggest risk is that the Merck KGaA acquisition does not close. Closing needs shareholder approval and regulatory approvals, including the Hart-Scott-Rodino process. If the deal breaks, the stock would likely trade on standalone biotech fundamentals instead of the $47.00 cash price.
Deal terms change or come with conditions
High impact · Low oddsRegulators could ask for changes, or another closing condition could create delay or uncertainty. The internal open question is whether all approvals arrive without material conditions. Even a delay can matter for a merger arbitrage stock because time reduces the value of waiting for cash.
Business disruption during the waiting period
Medium impact · Medium oddsA pending sale can distract management and make employees, doctors, suppliers, and partners uncertain. SpringWorks also faces limits on what it can do while the merger agreement is active. Those limits could stop it from taking actions that might help the standalone business.
Termination fee drains cash
Medium impact · Low oddsSpringWorks may owe Merck KGaA a $145.6 million termination fee if the agreement ends under certain conditions. That would hurt the cash position if the company had to continue alone. It would also reduce flexibility for launches and trials.
Standalone launch risk returns if the deal breaks
High impact · Medium oddsOGSIVEO and GOMEKLI are real commercial products, but they still need strong uptake, payer coverage, and doctor adoption. Q1 2025 sales were encouraging, but a failed merger would shift attention back to quarter-by-quarter execution. Europe launches and pipeline spending would also matter more.